Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18961644 | METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSIS | November 2024 | March 2026 | Abandon | 15 | 2 | 1 | Yes | No |
| 18743333 | Molybdenum (0) Precursors For Deposition Of Molybdenum Films | June 2024 | September 2025 | Allow | 15 | 1 | 1 | No | No |
| 18672819 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIA | May 2024 | March 2026 | Abandon | 22 | 1 | 1 | No | No |
| 18660695 | Hepatitis B Antiviral Agents | May 2024 | August 2025 | Allow | 15 | 1 | 1 | No | No |
| 18660815 | CD73 INHIBITORS | May 2024 | June 2025 | Allow | 14 | 0 | 1 | No | No |
| 18627949 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | April 2024 | January 2026 | Abandon | 21 | 1 | 1 | No | No |
| 18605925 | PROCESS FOR THE PREPARATION OF HIGH PURITY NORBORNENE SILYL ETHERS | March 2024 | April 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18586477 | SUPERABSORBENT MATERIALS AND METHODS OF MAKING THE SAME | February 2024 | January 2026 | Abandon | 23 | 2 | 0 | No | No |
| 18439896 | METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING SALVIANOLIC ACID B | February 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18422511 | COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER | January 2024 | August 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18414679 | POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSS | January 2024 | March 2025 | Allow | 14 | 0 | 1 | Yes | No |
| 18519938 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | November 2023 | December 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18511417 | USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS | November 2023 | December 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18491943 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | October 2023 | October 2024 | Allow | 12 | 1 | 0 | No | No |
| 18285803 | NOVEL CARBONYLATION CATALYSTS AND METHODS OF MAKING THE SAME | October 2023 | July 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18374543 | Oligosaccharide Compound for Inhibiting Intrinsic Coagulation Factor X-Enzyme Complex, and Preparation Method Therefor and Uses Thereof | September 2023 | December 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18470776 | PURIFICATION OF TRIMETHYLSILANOL | September 2023 | May 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18369456 | HYDROPHILIC LINKERS AND CONJUGATES THEREOF | September 2023 | November 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18469292 | OLIGOSACCHARIDE LINKER, LINKER-PAYLOAD COMPRISING THE SAME AND GLYCAN CHAIN-REMODELED ANTIBODY-DRUG CONJUGATE, PREPARATION METHODS AND USES THEREOF | September 2023 | January 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18459683 | COMPOSITIONS CONTAINING DECITABINE, 5AZACYTIDINE AND TETRAHYDROURIDINE AND USES THEREOF | September 2023 | January 2025 | Abandon | 16 | 1 | 1 | No | No |
| 18455007 | NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF | August 2023 | July 2025 | Allow | 23 | 1 | 1 | No | No |
| 18365920 | AFFINITY MEDICANT CONJUGATE | August 2023 | January 2025 | Allow | 18 | 2 | 1 | No | No |
| 18227627 | NATURAL HYDROCOLLOID SYSTEMS FOR PET FOOD COMPOSITIONS, PET FOOD COMPOSITIONS COMPRISING SAME, AND PREPARATIONS THEREOF | July 2023 | July 2025 | Allow | 24 | 2 | 1 | No | No |
| 18274414 | Process For The Preparation of Mixed Polyol-Carboxylic Acid EstersE | July 2023 | January 2026 | Allow | 30 | 0 | 0 | Yes | No |
| 18225405 | COMPOSITIONS AND METHODS FOR TREATING ELASTIC FIBER BREAKDOWN | July 2023 | October 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18343155 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF THERAPEUTIC NANOPARTICLES | June 2023 | October 2025 | Abandon | 28 | 1 | 1 | No | No |
| 18330757 | METHODS FOR TREATING ACUTE MYELOID LEUKEMIA AND RELATED CONDITIONS | June 2023 | May 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18328433 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | June 2023 | March 2025 | Allow | 21 | 1 | 1 | No | No |
| 18203678 | POLYMORPHIC FORMS OF RAD1901-2HCL | May 2023 | April 2025 | Allow | 23 | 2 | 0 | Yes | No |
| 18445213 | -ent-19-norprogesterone, compositions and uses thereof to treat traumatic brain injury (TBI), including concussions- | May 2023 | October 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18198258 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | May 2023 | October 2023 | Allow | 5 | 1 | 0 | No | No |
| 18036881 | A PROCESS FOR RECYCLING OF POLYETHYLENE TEREPHTHALATE (PET) WASTE | May 2023 | November 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18315446 | CATIONIC SULFONAMIDE AMINO LIPIDS AND AMPHIPHILIC ZWITTERIONIC AMINO LIPIDS | May 2023 | October 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 18309072 | SYNTHESIS AND USE OF PRECURSORS FOR VAPOR DEPOSITION OF TUNGSTEN CONTAINING THIN FILMS | April 2023 | November 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 18306601 | CANCER TREATMENT | April 2023 | July 2024 | Allow | 15 | 3 | 0 | No | Yes |
| 18138432 | DEOXYNUCLEOSIDE THERAPY FOR DISEASES CAUSED BY UNBALANCED NUCLEOTIDE POOLS INCLUDING MITOCHONDRIAL DNA DEPLETION SYNDROMES | April 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18032668 | METHOXYPROPANOLS SEPARATION COMBINING MEMBRANE SEPARATION AND DISTILLATION | April 2023 | November 2025 | Allow | 31 | 1 | 0 | No | No |
| 18032039 | OLEFIN POLYMERIZATION CATALYSTS BEARING A 6-AMINO-N-ARYL AZAINDOLE LIGAND | April 2023 | January 2026 | Allow | 34 | 0 | 1 | Yes | No |
| 18135118 | MOFS/COFS HETEROJUNCTION COMPOSITE PHOTOCATALYST AND PREPARATION METHOD AND APPLICATION THEREOF | April 2023 | March 2026 | Allow | 35 | 1 | 0 | No | No |
| 18029723 | PLASTICIZER COMPOSITION AND RESIN COMPOSITION COMPRISING THE SAME | March 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18189943 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | March 2023 | May 2025 | Allow | 26 | 1 | 1 | No | No |
| 18124697 | AMINOCARBONYLCARBAMATE COMPOUNDS | March 2023 | April 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18120596 | FREEZE-DRIED ALGINIC ACID PREPARATION | March 2023 | August 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18174783 | COMPOSITIONS AND METHODS FOR ALTERING MACROPHAGE PHENOTYPE | February 2023 | October 2025 | Abandon | 31 | 1 | 1 | No | No |
| 18172731 | Photochemical Separations and Compositions | February 2023 | May 2025 | Allow | 26 | 2 | 0 | No | No |
| 18106149 | CONJUGATED OLIGONUCLEOTIDE COMPOUNDS, METHODS OF MAKING AND USES THEREOF | February 2023 | February 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18161136 | COMPOSITIONS AND METHODS OF TREATMENT USING NICOTINAMIDE MONONUCLEOTIDE | January 2023 | February 2025 | Allow | 25 | 2 | 1 | Yes | No |
| 18101258 | HEPATITIS B ANTIVIRAL AGENTS | January 2023 | February 2024 | Allow | 12 | 1 | 0 | No | No |
| 18152993 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | January 2023 | March 2025 | Allow | 26 | 1 | 1 | No | No |
| 18087587 | ANTIMICROBIAL ORGANOSILANES | December 2022 | April 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18068346 | 17A-MONOESTERS AND 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18009203 | THERAPEUTICS FOR TREATMENT OF COVID-19 SYMPTOMS | December 2022 | February 2026 | Allow | 38 | 0 | 1 | Yes | No |
| 18009287 | COMPOSITION AND METHOD FOR NEW THERAPEUTIC AGENTS INCLUDING GUANIDINIUM-PRESENTING DENDRIMERS AND BRANCHED STRUCTURES | December 2022 | February 2026 | Allow | 38 | 1 | 1 | No | No |
| 18077921 | PURINE DIONES AS WNT PATHWAY MODULATORS | December 2022 | October 2025 | Allow | 34 | 3 | 1 | Yes | No |
| 18073595 | METHOD FOR SYNTHESIZING NANOHYBRID FOR BONE TISSUE ENGINEERING | December 2022 | September 2025 | Allow | 34 | 0 | 0 | No | No |
| 17989131 | SILYLATED ORGANOMODIFIED COMPOUNDS | November 2022 | October 2024 | Allow | 23 | 2 | 2 | Yes | No |
| 17985045 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | November 2022 | March 2026 | Allow | 40 | 1 | 1 | No | No |
| 17979450 | HYALURONAN CONJUGATES AND USES THEREOF | November 2022 | August 2024 | Allow | 21 | 2 | 0 | No | No |
| 18051125 | CD73 INHIBITORS | October 2022 | February 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 17976101 | MUSCLE REGENERATION | October 2022 | January 2025 | Abandon | 26 | 1 | 1 | No | No |
| 17997212 | BETA THYMOSIN PEPTIDES FOR TREATING VIRAL INFECTIONS | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 18049341 | PROCESS FOR PREPARING GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES | October 2022 | February 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18048504 | TREATMENTS OF PROSTATE CANCER | October 2022 | October 2023 | Allow | 12 | 2 | 0 | No | No |
| 18048293 | PEPTIDE PLATINUM COMPLEXES AND METHODS OF USE THEREOF | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17918652 | OPHTHALMIC LIQUID COMPOSITION COMPRISING LOW MOLECULAR WEIGHT LINEAR HYALURONIC ACID | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17917562 | Method for the dehydrogenation and methylation of silanes with methyl chloride | October 2022 | December 2024 | Allow | 26 | 1 | 0 | No | No |
| 17995196 | IMMUNOMODULATORS | September 2022 | June 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17912647 | LIPOPHILIC ENANTIOMERS OF DESACETYLGLUCOSAMINE MURAMYL DIPEPTIDE WITH ANTI-INFLAMMATORY AND GROWTH PROMOTING ACTIVITY | September 2022 | August 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17946416 | INDUCTION OF SYNTHETIC LETHALITY WITH EPIGENETIC THERAPY | September 2022 | June 2025 | Allow | 33 | 2 | 1 | Yes | Yes |
| 17910865 | METHOD FOR PRODUCING ORGANIC SILICON COMPOUND HAVING KETIMINE STRUCTURE | September 2022 | January 2026 | Allow | 40 | 2 | 0 | No | No |
| 17802859 | Halogenated Tetrasilyl Boranates | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17801628 | NON-CRYOGENIC SYNTHESIS OF HETEROATOM-BRIDGE PRECURSORS OF METAL-LIGAND COMPLEX CATALYSTS | August 2022 | May 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17893777 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING CORONARY DISORDERS | August 2022 | April 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17800211 | METHOD OF PREPARING SILANOLS WITH SELECTIVE CYTOCHROME P450 VARIANTS AND RELATED COMPOUNDS AND COMPOSITIONS | August 2022 | October 2024 | Allow | 26 | 1 | 0 | No | No |
| 17800131 | TAFOXIPARIN FOR THE TREATMENT OF PREECLAMPSIA | August 2022 | November 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17820242 | METHOD FOR PRODUCING AND PURIFYING RNA, COMPRISING AT LEAST ONE STEP OF TANGENTIAL FLOW FILTRATION | August 2022 | May 2023 | Allow | 8 | 1 | 0 | No | No |
| 17878747 | CANCER TREATMENTS | August 2022 | March 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17796535 | RAW MATERIAL FOR CHEMICAL DEPOSITION CONTAINING ORGANORUTHENIUM COMPOUND, AND CHEMICAL DEPOSITION METHOD USING THE RAW MATERIAL FOR CHEMICAL DEPOSITION | July 2022 | March 2026 | Allow | 44 | 1 | 1 | Yes | No |
| 17795207 | METHOD FOR PRODUCING HALOGENATED HYDROCARBON MAGNESIUM COMPOUND AND METHODS FOR PRODUCING TERTIARY ALCOHOL COMPOUND AND ORGANOSILICON COMPOUND | July 2022 | January 2025 | Allow | 30 | 1 | 1 | No | No |
| 17871515 | COMPOSITIONS COMPRISING CITRULLINE AND LEUCINE AND THEIR USE IN THE TREATMENT OF DIABETES AND METABOLIC SYNDROME | July 2022 | December 2023 | Allow | 17 | 1 | 0 | Yes | No |
| 17794259 | LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, SENSOR, LIQUID CRYSTAL LENS, OPTICAL COMMUNICATION DEVICE, AND ANTENNA | July 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17869352 | SEMICONDUCTING LIGHT EMITTING MATERIAL | July 2022 | October 2024 | Abandon | 27 | 1 | 2 | No | No |
| 17859953 | SILICON PRECURSOR MATERIALS, SILICON-CONTAINING FILMS, AND RELATED METHODS | July 2022 | September 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17809239 | PREPARATION METHOD OF FUNCTIONAL SILANES | June 2022 | January 2023 | Allow | 7 | 1 | 0 | No | No |
| 17848468 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | June 2022 | May 2023 | Allow | 10 | 0 | 0 | Yes | No |
| 17848462 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | June 2022 | May 2023 | Allow | 11 | 0 | 0 | No | No |
| 17848466 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | June 2022 | May 2023 | Allow | 10 | 0 | 0 | No | No |
| 17848456 | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE-CARRIER PROTEIN CONJUGATES | June 2022 | May 2023 | Allow | 10 | 0 | 0 | No | No |
| 17787806 | FUNCTIONALISATION OF 1,3-ALPHA-DIENES (I) | June 2022 | April 2025 | Abandon | 34 | 1 | 1 | No | No |
| 17786570 | SELECTIVE PREPARATION OF VINYL- AND ETHYL-FUNCTIONALIZED CHLOROSILANES | June 2022 | February 2025 | Allow | 32 | 2 | 0 | Yes | No |
| 17842042 | NICOTINAMIDE RIBOSIDE FOR USE IN TREATING OR PREVENTING LIVER DAMAGE | June 2022 | August 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17784082 | PROCESS FOR SYNTHESIZING ALKENYL DISILOXANE | June 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17805479 | FOLIC COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC NEUROPATHIES | June 2022 | March 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17833780 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | June 2022 | March 2024 | Allow | 22 | 1 | 1 | No | No |
| 17805634 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | June 2022 | April 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17828591 | HYDROGEN-BONDED ORGANIC FRAMEWORK (HOF) FOR WATER UPTAKE | May 2022 | August 2022 | Allow | 2 | 0 | 0 | No | No |
| 17780559 | PROCESS FOR PREPARING TRIMETHYLCHLOROSILANE | May 2022 | February 2025 | Allow | 33 | 2 | 0 | No | No |
| 17749293 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | May 2022 | December 2023 | Allow | 19 | 1 | 0 | No | No |
| 17756234 | LIQUID EMBOLIC MATERIAL COMPOSITION | May 2022 | March 2026 | Allow | 46 | 1 | 1 | Yes | No |
| 17738435 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | May 2022 | January 2024 | Abandon | 20 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BAKSHI, PANCHAM.
With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 34.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner BAKSHI, PANCHAM works in Art Unit 1623 and has examined 636 patent applications in our dataset. With an allowance rate of 72.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.
Examiner BAKSHI, PANCHAM's allowance rate of 72.6% places them in the 36% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by BAKSHI, PANCHAM receive 1.55 office actions before reaching final disposition. This places the examiner in the 28% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BAKSHI, PANCHAM is 25 months. This places the examiner in the 78% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +32.1% benefit to allowance rate for applications examined by BAKSHI, PANCHAM. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 32.7% of applications are subsequently allowed. This success rate is in the 69% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 35.5% of cases where such amendments are filed. This entry rate is in the 53% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 22.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 27% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 82.1% of appeals filed. This is in the 75% percentile among all examiners. Of these withdrawals, 43.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 72.7% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 51% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.0% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.